Related Experiment Video
Updated: Aug 14, 2026
Inducible and Reversible Dominant-negative (DN) Protein Inhibition
Published on: January 7, 2019
Rb-driven transcription limits its tumour-suppressive effects in breast cancer
April C Watt1,2, Antonio Ahn1,2, Catherine Blyth1,2
1Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Abstract:
The retinoblastoma protein (Rb) is a tumour suppressor best known for repressing E2F transcription factors and halting cell cycle progression1. In hormone receptor-positive (HR+) breast cancer, CDK4/6 inhibitors activate Rb by preventing its phosphorylation, forming a key component of current endocrine therapy regimens2. How pharmacologically activated Rb remodels chromatin and influences transcription beyond cell cycle arrest remains poorly understood. Here we show that CDK4/6 inhibition induces redistribution of hypophosphorylated Rb to promoters and enhancers. Although Rb predictably binds to cell cycle gene promoters to repress transcription, at other sites, it unexpectedly promotes expression of oestrogen-responsive genes by integrating into oestrogen receptor (ER)-rich transcriptional hubs. CDK4/6 inhibition enhances ER target gene expression in breast cancer cells, patient-derived xenografts and clinical HR+ breast cancer samples in an Rb-dependent manner. This reprogramming is mediated in part by KDM5A, whose interaction with Rb contributes to gene regulation at these loci. Critically, components of this Rb-driven ER transcriptional program are pro-proliferative. In endocrine-sensitive tumours, this effect can be neutralized with anti-oestrogen therapy, explaining therapeutic synergy. In endocrine-resistant settings such as ESR1-mutant breast cancer, the program persists, limiting the therapeutic efficacy of CDK4/6 inhibition. These findings reframe Rb as a dual-function transcriptional regulator that, although enforcing cell cycle arrest, can also activate programs that counteract its tumour suppressor function.
Insights
Retinoblastoma protein (Rb) unexpectedly promotes gene expression in hormone receptor-positive breast cancer treated with CDK4/6 inhibitors. This dual function impacts endocrine therapy efficacy and resistance.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Retinoblastoma protein (Rb) is a tumor suppressor regulating cell cycle progression by inhibiting E2F transcription factors.
- In hormone receptor-positive (HR+) breast cancer, CDK4/6 inhibitors activate Rb, a critical part of endocrine therapy.
- The mechanisms by which pharmacologically activated Rb influences chromatin and transcription beyond cell cycle arrest are not fully understood.
Purpose of the Study:
- To investigate how CDK4/6 inhibition-induced Rb activation remodels chromatin and affects gene transcription in HR+ breast cancer.
- To elucidate the role of Rb in regulating oestrogen receptor (ER) target genes and its implications for endocrine therapy.
Main Methods:
- Chromatin immunoprecipitation to assess Rb binding to promoters and enhancers.
- Gene expression analysis in breast cancer cells, patient-derived xenografts, and clinical samples.
- Investigation of the interaction between Rb and KDM5A in gene regulation.
Main Results:
- CDK4/6 inhibition causes hypophosphorylated Rb to redistribute to promoters and enhancers.
- Rb represses cell cycle genes but also promotes oestrogen-responsive gene expression by integrating into ER transcriptional hubs.
- This Rb-driven pro-proliferative program enhances ER target gene expression in an Rb-dependent manner, impacting therapeutic response.
Conclusions:
- Rb acts as a dual transcriptional regulator, capable of both enforcing cell cycle arrest and activating pro-proliferative programs.
- The Rb-driven ER transcriptional program contributes to therapeutic synergy in endocrine-sensitive tumors but limits CDK4/6 inhibitor efficacy in endocrine-resistant settings (e.g., ESR1-mutant breast cancer).
- Understanding Rb's complex role is crucial for optimizing breast cancer treatment strategies.
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:23Abnormal Proliferation
01:22MicroRNAs
01:22MicroRNAs
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...